<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Heat Shock Proteins (HSPs)</th>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Molecular chaperones</td>
</tr>
<tr>
<td class="label">Key Members</td>
<td>HSP70, HSP90, HSP60, HSP40, small HSPs (sHSP)</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Protein folding, refolding, degradation</td>
</tr>
<tr>
<td class="label">Induction</td>
<td>Heat stress, oxidative stress, proteotoxic stress</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/als">ALS</a>, Huntington's Disease</td>
</tr>
</table>
Heat Shock Proteins (HSPs) are a family of molecular chaperones that play essential roles in cellular protein homeostasis. Named for their initial discovery as proteins whose expression is induced by heat stress, HSPs have evolved to be critical guardians against proteotoxic stress throughout the body, including the brain. In neurodegenerative diseases, where protein aggregation is a hallmark feature, HSPs have emerged as both protective agents and potential therapeutic targets.
Heat shock proteins are classified by their molecular weight and function:
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Heat Shock Proteins (HSPs)</th>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Molecular chaperones</td>
</tr>
<tr>
<td class="label">Key Members</td>
<td>HSP70, HSP90, HSP60, HSP40, small HSPs (sHSP)</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Protein folding, refolding, degradation</td>
</tr>
<tr>
<td class="label">Induction</td>
<td>Heat stress, oxidative stress, proteotoxic stress</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td><a href="/diseases/alzheimers">Alzheimer's Disease</a>, <a href="/diseases/parkinsons-disease">Parkinson's Disease</a>, <a href="/diseases/als">ALS</a>, Huntington's Disease</td>
</tr>
</table>
Heat Shock Proteins (HSPs) are a family of molecular chaperones that play essential roles in cellular protein homeostasis. Named for their initial discovery as proteins whose expression is induced by heat stress, HSPs have evolved to be critical guardians against proteotoxic stress throughout the body, including the brain. In neurodegenerative diseases, where protein aggregation is a hallmark feature, HSPs have emerged as both protective agents and potential therapeutic targets.
Heat shock proteins are classified by their molecular weight and function:
| Family | Members | Primary Function |
|--------|---------|-----------------|
| HSP70 | HSPA1A, HSPA1B, HSPA8 (HSC70), GRP78 (BiP) | Protein folding, disaggregation, degradation |
| HSP90 | HSP90AA1, HSP90AB1, GRP94 | Client protein maturation, quality control |
| HSP60 | HSPD1 | Mitochondrial protein folding |
| HSP40 | DNAJA1, DNAJB1 | Co-chaperones, substrate delivery |
| sHSPs | αA-crystallin (CRYAA), αB-crystallin (CRYAB), HspB1 | Stabilization, prevent aggregation |
In neurons, HSPs are particularly important due to the post-mitotic nature of these cells — they cannot simply divide to escape proteotoxic stress. The accumulation of misfolded proteins in Alzheimer's Disease (amyloid-beta, tau), Parkinson's Disease (alpha-synuclein), ALS (TDP-43, SOD1), and Huntington's Disease (mutant huntingtin) creates an overwhelming burden on the cellular protein homeostasis machinery.
HSP70 proteins consist of two functional domains:
The cycle of substrate binding and release is regulated by co-chaperones:
In Alzheimer's disease, HSP70 family members have been shown to:
Alpha-synuclein aggregation is a central pathological feature of Parkinson's disease, and HSP70 has demonstrated protective effects:
In ALS, mutant SOD1 and TDP-43 aggregates overwhelm the protein quality control system:
HSP90 is unique among HSPs in that it primarily functions as a "client protein" chaperone, rather than a general folding chaperone. HSP90 stabilizes over 200 client proteins, many of which are signaling kinases, transcription factors, and steroid receptors.
In the brain, key HSP90 clients include:
HSP90 inhibitors have been extensively studied in neurodegenerative disease models:
| Inhibitor | Mechanism | Development Status |
|-----------|-----------|------------------|
| Geldanamycin | Natural product, binds HSP90 ATP pocket | Preclinical only (toxicity) |
| 17-AAG (Tanespimycin) | Synthetic geldanamycin analog | Clinical trials in AD/PD |
| 17-DMAG | More water-soluble analog | Preclinical |
| PU-H71 | Purine-scaffold inhibitor | Preclinical |
The rationale for HSP90 inhibition in neurodegeneration:
αB-crystallin is one of the most studied sHSPs in neurodegeneration:
HSP27 is another sHSP with neuroprotective properties:
Several compounds can induce HSP expression:
| Compound | Mechanism | Stage |
|----------|-----------|-------|
| Geranylgeranylacetone (GGA) | HSP70 transcriptional inducer | Clinical trials in PD |
| Arimoclomol | HSP70 co-inducer | Phase 3 trial in ALS |
| Sodium phenylbutyrate (4-PBA) | HDAC inhibitor, HSP inducer | Preclinical |
| Geldanamycin derivatives | HSP90 inhibitor with HSP70 induction | Preclinical |
Arimoclomol has shown particular promise in ALS, extending survival in SOD1 mutant mice. It functions as a co-inducer of HSPs, amplifying the heat shock response without causing the cellular stress that direct HSP90 inhibition would cause.
Viral delivery of HSP genes:
Direct modulators of HSP activity:
HSPs work in concert with other protein quality control components:
| Partner | Interaction |
|---------|-------------|
| HSP40 (DNAJA/B) | Delivers substrates to HSP70 |
| HSP110 (HSPA4) | Nucleotide exchange factor for HSP70 |
| Bag family proteins | Co-chaperones that regulate HSP70 activity |
| CHIP (STUB1) | E3 ubiquitin ligase that partners with HSP70/HSP90 |
| p62 (SQSTM1) | Autophagy receptor for ubiquitinated proteins |
Current clinical approaches targeting HSPs in neurodegeneration:
| Trial | Compound | Disease | Phase | Outcome |
|-------|----------|---------|-------|---------|
| NCT00706147 | Arimoclomol | ALS | Phase 2 | Positive results |
| NCT0304418 | Arimoclomol | ALS | Phase 3 | Ongoing |
| NCT01065961 | 17-AAG | AD | Phase 1 | Terminated (toxicity) |
| NCT01682988 | Geldanamycin derivative | PD | Phase 1 | Completed |
Interactive diagram showing HEAT SHOCK PROTEINS's key relationships in the SciDEX knowledge graph (5 connections shown).